

## Special Issue

# Drug Repurposing and Reformulation for Cancer Treatment: 2nd Edition

### Message from the Guest Editors

Drug repurposing is a drug development strategy that focuses on establishing new therapeutic indications for FDA-approved or previously discarded drugs. The availability of pharmacokinetic, tolerability and toxicological profiles of the drug considered for repurposing is a major advantage, able to accentuate the clinical translation of the repurposed drug with a concomitant reduction in the development time and cost. We are pleased to invite you to submit original contributions and/or reviews highlighting the potential of FDA-approved or previously discarded drugs in curbing cancer initiation, progression, and/or metastasis, and drug resistance. We also welcome contributions concerning the development of repurposed drug delivery systems to improve their bioavailability and/or targeting to augment therapeutic outcomes in various cancers. We will consider contributions demonstrating in vitro and/or in vivo preclinical evidence of drug repurposing and/or reformulation for cancer therapy, and encourage contributions focusing on the exploration of repurposed drugs as an adjunct to standard chemo- and/or radiotherapy.

---

### Guest Editors

Prof. Dr. Arati Sharma

Prof. Dr. Dhimant Desai

Dr. Abhijit Date

---

### Deadline for manuscript submissions

1 June 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.4**  
**CiteScore 8.8**  
**Indexed in PubMed**



[mdpi.com/si/219117](https://mdpi.com/si/219117)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)